What are the symptoms and treatment options for Multinodular Goiter (MNG)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Multinodular goiter (MNG) is a condition where the thyroid gland becomes enlarged with multiple nodules, and the most recent and highest quality study recommends that treatment depends on the size, symptoms, and whether the nodules are producing excess thyroid hormones 1. The symptoms of MNG include:

  • A visible swelling in the neck
  • Difficulty swallowing or breathing
  • Hoarseness
  • Rarely, hyperthyroidism symptoms like weight loss, anxiety, and heat intolerance Most multinodular goitres are benign and asymptomatic, requiring only monitoring through regular physical examinations and thyroid function tests.

Treatment options for MNG include:

  • Watchful waiting for small, asymptomatic goitres
  • Levothyroxine to suppress thyroid growth in some cases, typically at doses of 1.6-1.8 mcg/kg daily
  • Antithyroid medications like methimazole (10-30 mg daily) or propylthiouracil (100-300 mg daily in divided doses) to normalize hormone levels for hyperthyroid goitres
  • Surgical removal (thyroidectomy) for large goitres causing compressive symptoms
  • Radioactive iodine therapy (typically a single dose of 10-29.9 mCi) as an alternative for hyperthyroid goitres in patients who are not surgical candidates The treatment approach is individualized based on the patient's age, overall health, and the specific characteristics of their goitre, with the goal of relieving symptoms and preventing complications while maintaining normal thyroid function 1. It is also important to note that fine needle aspiration cytology (FNAC) is an important technique that is used along with US for the diagnosis of thyroid nodules, and should be performed in any thyroid nodule >1 cm and in those <1 cm if there is any clinical or ultrasonographic suspicion of malignancy 1.

From the Research

Symptoms of Multinodular Goiter (MNG)

  • The clinical presentation of patients with multinodular goiter is variable and dependent on size, location, and the functional state of the thyroid tissue 2
  • The most frequent clinical symptoms are caused by compression and deviation of the trachea and range from dyspnoea to acute asphyxia 2
  • Nodular goiters may be asymptomatic, with normal TSH levels (nontoxic), or may be associated with systemic thyrotoxic symptoms (toxic MNG or Plummer's disease) 3
  • Symptoms can also include local compression symptoms attributed to the goiter, such as difficulty swallowing or breathing 3

Treatment Options for MNG

  • Indications for treatment in patients with MNG include hyperthyroidism, local compression symptoms attributed to the goiter, cosmesis, and concern about malignancy based on FNA results 3
  • Treatment options for MNG include:
    • Surgery: preferred treatment for large nontoxic multinodular goiters with local compression symptoms 3, 2
    • Radioiodine therapy: effective therapy for many patients with toxic MNG, and can also be used for non-toxic MNG 3, 4, 5, 2, 6
    • Levothyroxine suppression therapy: can be used to decrease and control MNG size, but its use is controversial and should not be used in patients with suppressed serum TSH levels 3
    • Recombinant human thyrotropin (rhTSH)-aided radioiodine therapy: can increase radioiodine uptake and reduce thyroid volume of the multinodular goiter, but its benefits and risks are still being studied 4, 5, 6

Diagnostic Evaluation of MNG

  • Diagnostic evaluation of patients with nodular goiters consists of clinical evaluation, biochemical testing, FNA, and imaging studies 3
  • The serum TSH level is a sensitive and reliable index of thyroid function 3
  • FNA results are pivotal to assess cancer risk in patient management for prominent palpable and suspicious nodules 3
  • Imaging studies, such as chest radiography, high-resolution ultrasonography, and computed tomography, can help to delineate the size and extent of a goiter in evaluating compression symptoms 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Multinodular goitre: not always harmless].

Nederlands tijdschrift voor geneeskunde, 2014

Research

Evaluation and management of multinodular goiter.

Otolaryngologic clinics of North America, 1996

Research

Radioiodine treatment for non-toxic goitre.

F1000 medicine reports, 2009

Related Questions

What are the treatment options for a 77-year-old patient with low Thyroid-Stimulating Hormone (TSH) levels, multi-nodular goiter, and a benign thyroid nodule biopsy, who has hyperthyroidism (14% uptake with focal increased activity in the right upper thyroid lobe) and did not tolerate Methimazole (Tapazole)?
What is the recommended treatment for a young female with a multinodular goitre and elevated TSH levels?
What is the recommended workup and management for a 40-year-old male with an incidental finding of a multinodular goitre and a normal Thyroid-Stimulating Hormone (TSH) level?
What are the indications for surgery in multinodular non-toxic (MNTG) goitre?
What is the initial approach to managing a patient with multinodular nontoxic goiter?
What is the maximum dose of vasopressin (antidiuretic hormone) for intrauterine fibroid injection?
What is the maximum dose of vasopressin (Vasopressin) for intrauterine fibroid injection and its half-life?
What is the diagnosis and treatment for Multinodular Goiter (MNG)?
What is the significance of elevated Thyroid-Stimulating Hormone (TSH) and Thyroxine (T4) levels in a patient 4 months post-thyroidectomy and 1 month post-Radioactive Iodine (RAI) therapy, currently on 175 micrograms of Levothyroxine (T4 replacement therapy)?
What is the significance of elevated Thyroid-Stimulating Hormone (TSH) and Thyroxine (T4) levels in a patient 4 months post-thyroidectomy and 1 month post-Radioactive Iodine (RAI) therapy, currently on 175 micrograms of Levothyroxine (T4 replacement therapy)?
What is the management approach for a patient 4 months post-thyroidectomy and 1 month post-radioactive iodine (RAI) therapy, currently on 175 micrograms of Levothyroxine (thyroxine), presenting with elevated Thyroid-Stimulating Hormone (TSH) and thyroxine (T4) levels, with a target TSH of less than 0.1?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.